Medicxi — 2025 Investments
4 investments dated 2025 · listed companies and verified rows first · show all
BiotechPhiladelphia, US
William Hinshaw(Executive Officer, Director)Jeff Sacher(Chief Financial Officer)Matthew Ros(Chief Executive Officer, President and Secretary)
BoardErez Chimovits(Director)inMatthew Foy(Director)
Board seatGiovanni Mariggi· per SEC Form D · $46M raise · filed May 2025
Co-investors3B Future Health FundOrbiMed
Rivus develops oral medicines for cardiometabolic health using its proprietary development platform.
BiotechDigital HealthCharlottesville, US
Allen Cunningham(Executive Officer, Director)Nancy Hargreaves(Executive Officer)Jayson Dallas(Executive Officer, Director)Shaharyar Khan(Executive Officer, Director)
BoardDerek DiRocco(Director)in
Board seatFrancesco De Rubertis· per SEC Form D
Co-investorsLongitude CapitalRA Capital
Curevo Vaccine is a clinical-stage biotech company developing non-mRNA vaccines, with a lead adjuvanted subunit vaccine candidate (amezosvatein/CRV-101) for shingles and chickenpox.
BiotechHealthtech
Co-investorsAdjuvant CapitalOrbiMedRA CapitalSanofi VenturesHBM Healthcare InvestmentsJanus Henderson Investors
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.